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Abstract
Purinergic ionotropic P2X receptors are a family of cation-permeable channels that bind extracellular adenosine
5k-triphosphate. In particular, convergent lines of evidence have recently highlighted P2X4 receptors as a
potentially critical target in the regulation of multiple nervous and behavioural functions, including pain,
neuroendocrine regulation and hippocampal plasticity. Nevertheless, the role of the P2X4 receptor in behavioural
organization remains poorly investigated. To study the effects of P2X4 activation, we tested the acute effects of its
potent positive allosteric modulator ivermectin (IVM, 2.5–10 mg/kg i.p.) on a broad set of paradigms capturing
complementary aspects of perceptual, emotional and cognitive regulation in mice. In a novel open field, IVM did
not induce significant changes in locomotor activity, but increased the time spent in the peripheral zone. In
contrast, IVM produced anxiolytic-like effects in the elevated plus maze and marble burying tasks, as well as
depression-like behaviours in the tail-suspension and forced swim tests. The agent induced no significant be-
havioural changes in the conditioned place preference test and in the novel object recognition task. Finally, the
drug induced a dose-dependent decrease in sensorimotor gating, as assessed by pre-pulse inhibition (PPI) of the
acoustic startle reflex. In P2X4 knockout mice, the effects of IVM in the open field and elevated plus maze were
similar to those observed in wild type mice ; conversely, the drug significantly increased startle amplitude and
failed to reduce PPI. Taken together, these results suggest that P2X4 receptors may play a role in the regulation of
sensorimotor gating.
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First published online 17 September 2012
Key words : Anxiety, depression, ivermectin, pre-pulse inhibition of the startle, P2X4 purinergic receptors.
Introduction
Purinergic ionotropic P2X receptors are a family of
hetero- and homotrimeric cation-permeable channels that
bind extracellular adenosine 5k-triphosphate (North,
2002). The biophysical and pharmacological properties of
P2X receptors are defined by their subunit composition
(Khakh & North, 2006). In particular, of the seven P2X
subunits characterized to date (termed P2X1 to P2X7),
recent evidence has highlighted P2X4 subunits as a
potentially interesting target in the regulation of nervous
functions. P2X4 subunits form homotrimeric receptors
with distinct functional properties (Bo et al. 1995; Soto
et al. 1996), as well as heteromers with other P2X subunits
(Guo et al. 2007; Nicke et al. 2005; Ormond et al. 2006; for
contrasting results, see Antonio et al. 2011). P2X4 re-
ceptors are abundant in the central nervous system
(Rubio & Soto, 2001 ; Tsuda et al. 2003) and involved in
the regulation of neuropathic pain (Tsuda et al. 2003;
Ulmann et al. 2008; Zhang et al. 2006), neuroendocrine
regulation (Zemkova et al. 2010) and hippocampal plas-
ticity (Baxter et al. 2011; Lorca et al. 2011; Sim et al. 2006).
Furthermore, P2X4 receptors have been recently shown to
modulate the activity of c-amino-butyric acid (GABA)A
(Jo et al. 2011) and N-methyl-D-aspartate glutamate
(Baxter et al. 2011) receptors. Recent studies have docu-
mented that some antidepressants may inhibit P2X4 re-
ceptors (Nagata et al. 2009), although this evidence
remains controversial in view of contrasting findings
(Sim & North, 2010 ; Toulme et al. 2010a). Furthermore,
converging lines of in vitro and in vivo evidence suggest
that P2X4 receptors may be an important therapeutic tar-
get for alcohol use disorders (Asatryan et al. 2010, 2011;
Kimpel et al. 2007; Popova et al. 2010; Tabakoff et al. 2009).
In contrast with this background, the pharmacological
armamentarium to probe P2X4 receptors is very limited.
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P2X4 receptors are poorly sensitive to P2X receptor
antagonists, such as suramin and pyridoxal phosphate-6-
azo-(benzene-2,4-disulfonic acid) (Buell et al. 1996).
Conversely, research has shown that the anti-parasitic
ivermectin (IVM) acts as a potent positive allosteric
regulator of P2X4 in either its homomeric or heteromeric
configurations, but does not interact with other P2X re-
ceptors (Khakh et al. 1999; Priel & Silberberg, 2004). IVM
is a mixture of semi-synthetic macrocyclic lactone dis-
accharides derived by hydroxylation of avermectins B1a
and B1b, natural fermentation products of the actino-
mycete Streptomyces avermitilis. IVM is widely adopted in
human and veterinarian medicine as a broad-spectrum
anthelmintic and insecticide agent (Geary, 2005 ; Richard-
Lenoble et al. 2003), with high therapeutic index and
limited side-effects. The anti-parasitic mechanism of IVM
is based on the activation of glutamate-gated chloride
channels specific to invertebrates (Cully et al. 1994;
Vassilatis et al. 1997).
In mammalians, in addition to its action on P2X4
receptors, IVM has been shown to activate GABAA re-
ceptors and exert weak effects on the positive modulation
of other ionotropic channels, including glycine, and
acetylcholine nicotinic receptors (Collins & Millar, 2010;
Dawson et al. 2000; Krause et al. 1998; Sattelle et al. 2009;
Shan et al. 2001; Sung et al. 2009).
Previous studies have revealed that long-term admin-
istration of IVM has subtle behavioural effects on loco-
motor and sensory reactivity of mice (Davis et al. 1999) ;
furthermore, this substance has been shown to exert
anxiolytic-like properties in rats (de Spinosa et al. 2002).
Capitalizing on our discovery that IVM antagonizes
ethanol-mediated inhibition of P2X4 receptors (Asatryan
et al. 2010), we recently found that this compound
reduces alcohol consumption (Yardley et al. 2012).
Nevertheless, to the best of our knowledge, the acute
behavioural effects of IVM have not been the object of
systematic investigations. Thus, in consideration of the
potential role of P2X4 receptors in the regulation of brain
functions, we addressed the present study to determine
the perceptual, emotional and cognitive impact of IVM in
C57BL/6 mice, using a broad spectrum of well-validated
paradigms targeting complementary aspects of behav-
ioural regulation.
Materials and method
Animals
Studies were performed on drug-naive, C57BL/6J
(Jackson Laboratory, USA) wild-type (WT) and P2X4
knockout (KO) male mice, aged 6–10 wk at the time of
testing. P2X4 KO mice were generated and genotyped
according to previous protocols (Sim et al. 2006). Animals
were acclimatized to the housing facility for a minimum
of 1 wk and group-housed (four mice per cage) in poly-
carbonate cages, with ad libitum access to food and water.
The holding room was maintained at approximately
22 xC with a 12 :12 h light :dark cycle (lights on 06:00
hours). All procedures were in compliance with the
National Institute of Health guidelines and the protocols
were approved by the University of Southern California
Institutional Animal Care and Use Committee.
Generation and identification of KO P2X4
x/x mice
The current P2X4 KO colony in our laboratory was started
by rederivation (USC Transgenic Core, USA) of frozen
heterozygous P2X4
+/x embryos (via surrogate female
C57BL/6 mice (Jackson Laboratory). Presently, we are
maintaining the P2X4R KO colony using sixth generation
heterozygous P2X4
+/x backcrossed onto C57BL/6J back-
ground. Upon weaning, offspring are genotyped, sep-
arated by sex and maintained in groups of four in
individually ventilated cages with free access to food and
water under a 12 :12 h light/dark cycle at 26¡1 xC.
Drugs
IVM (Norbrook Inc., USA) and its vehicle propylene
glycol (Alfa Aesar, USA) were diluted in a 0.9% saline
solution, to a concentration that would allow for an in-
jection volume of 0.01 ml/g body weight. Throughout all
experiments, IVM was injected 8 h before behavioural
testing, as our previous studies documented that the
maximal efficacy and the Tmax of the drug in brain and
plasma was reached at this time (Yardley et al. 2012).
Preliminary physical assessment
The impact of IVM in mice was tested on posture, gait,
heart rate, breathing frequency and neurological reflexes
(righting reflex, postural reflex, eye-blink reflex and
whisker-orienting reflex ; Davis et al. 1999).
Sticky tape test
Mice were briefly restrained and a circular piece of tape
was placed on the bottom of each forepaw. Mice were
then released and the latency to remove the first piece of
tape was recorded.
Hot plate
Mice were individually exposed to a hot plate (IITC Life
Science, USA) at 47.5 and 50 xC and the latency to lick
their paws was measured. We used a cut-off time of 40 s
to eliminate any potential tissue damage.
Novel open field
The open field was a Plexiglas square grey arena
(40r40 cm) surrounded by four black walls (40 cm high).
On the floor, two concentric zones of equivalent areas
were defined: a central square quadrant and a peripheral
frame directly adjacent to the walls. Mice were placed in
the centre and their behaviour was monitored for 5 min.
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Analysis of locomotor activity was performed using
Ethovision (Noldus Instruments, The Netherlands).
Behavioural measures included the distance travelled,
duration in the central zone, percent activity in the centre
(defined as the distance travelled in the centre divided by
the total distance travelled), meandering (defined as the
ratio of the turn-angle degrees over total distance ; Kalueff
et al. 2007), number of rearing episodes and percent time
moving (calculated as the time spent moving over the
total time).
Elevated plus maze
Behaviour in the elevated plus maze was monitored as
described elsewhere (Bortolato et al. 2009). The apparatus
was black Plexiglas with a light grey floor and consisted
of two open (25r5 cm) and two closed (25r5r5 cm)
arms, which extended from a central platform (5r5 cm)
at 60 cm from the ground. Mice were individually placed
on the central platform facing an open arm and their be-
haviour was observed for 5 min by an experimenter un-
aware of the genotype. An arm entry was counted when
all four paws were inside the arm. Behavioural measures
included time spent and entries into each partition of the
elevated plus maze, number of head dips, stretch-attend
postures (both defined as in Rodgers et al. 1992) and rears.
Marble burying
Marble burying was tested as previously described
(Bortolato et al. 2009). Briefly, mice were acclimatized for
10 min to novel cages (35r28 cm) filled with sawdust. At
the end of this phase, they were briefly removed and 20
glass marbles were placed on the surface of the cage at
even distances. Animals were then reintroduced into the
cages and their behaviour was monitored for the follow-
ing 10 min. The number of marbles buried, as well as the
frequency and overall duration of digging was scored. A
marble was considered buried if at least two-thirds of its
surface area was covered in sawdust.
Forced swim test
The forced swim test was performed as previously de-
scribed (Gobbi et al. 2005). Briefly, mice were habituated
to clear Plexiglas cylinders (40 cmr19 cm in diameter)
filled to 15 cm with water for 1 min. The water tempera-
ture was maintained at 30 xC. On the following day,
mice were re-exposed to the cylinder using the above-
mentioned conditions for 5 min. Environmental light was
kept at 300 lux. Animals were video-recorded and the
duration of immobility (s) and the latency to immobility
(s) were measured.
Tail suspension test
The tail suspension test was performed as described
elsewhere (Scott et al. 2008). Mice were individually
suspended by the tail using medical tape affixed to a
hook, at 30 cm from the floor. Environmental light was
kept at 300 lux. Animals were video-recorded for 6 min
and the duration of immobility (s), the latency to immo-
bility (s) and number of faecal boli were measured.
Conditioned place preference (CPP)
CPP was evaluated as previously described (Bortolato
et al. 2006; Maldonado et al. 1997). The apparatus con-
sisted of two different compartments (15r15r15 cm)
separated by a central neutral area (start compartment),
through two guillotine doors. The two compartments
featured different visual cues (striped or triangular pat-
terns) on the walls and tactile cues (square or chequered
grid) on the floor. The combinations of visual and tactile
cues were present in the compartments in a counter-
balanced order. The experiment was conducted with
a biased design and consisted of three consecutive
phases. In phase I (pre-conditioning), the animals were
habituated to the apparatus for 2 d and their initial side
preferences were recorded in a 15-min trial. Phase II
(training) lasted 10 d. On odd days, mice received IVM
or vehicle and were placed in the non-preferred (NP)
compartment (with the guillotine door closed) for
15 min; conversely, on even days, mice received vehicle
and were placed in the preferred compartment for
15 min. On the test day (post-conditioning, phase III), the
animals were given no treatment and were placed in the
start compartment, with free access to both sides for
15 min. IVM preference was measured as the difference
between the time spent in the drug-paired compartment
(NP) during the post-conditioning and pre-conditioning
phases.
Acoustic startle and pre-pulse inhibition (PPI) of the
startle reflex
Acoustic startle reflex and PPI were tested as previously
described (Bortolato et al. 2005). The apparatus used for
detection of startle reflex (San Diego Instruments, USA)
consisted of one standard cage placed in sound-
attenuated chambers with fan ventilation. Each cage
consisted of a Plexiglas cylinder of 3 cm diameter,
mounted on a piezoelectric accelerometric platform con-
nected to an analogue–digital converter. Background
noise and acoustic bursts were conveyed by two separate
speakers, each one properly placed so as to produce a
variation of sound within 1 dB across the startle cage.
Both speakers and startle cages were connected to a main
PC, which detected and analysed all chamber variables
with specific software. Before each testing session,
acoustic stimuli were calibrated via specific devices sup-
plied by San Diego Instruments. Mice were placed in a
cage for a 5-min acclimatization period with a 70 dB
white noise background, which continued for the re-
mainder of the session. Each session consisted of three
consecutive sequences of trials (periods). Unlike the first
and the third period – during which mice were presented
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with only five pulse-alone trials of 115 dB – the second
period consisted of a pseudorandom sequence of 40
trials, including 12 pulse-alone trials, 30 trials of pulse
preceded by 73, 76 and 82 dB pre-pulses (respectively
defined as PP3, PP6 and PP12; 10 for each level of pre-
pulse loudness) and eight no stimulus trials, where only
the background noise was delivered. The duration of
pulses and pre-pulses was 80 and 40 ms, respectively.
Pre-pulse–pulse delay amounted to 100 ms. Inter-trial
intervals were selected randomly between 10 and 15 s.
Percent PPI was calculated using the following formula :
100-[(mean startle amplitude for pre-pulse pulse trials/
mean startle amplitude for pulse alone trials)r100].
Novel object exploration and recognition
We used a modified version of the protocol described in
Bortolato et al. (2010). Mice were individually acclimat-
ized to Makrolon cages for 15 min each. The day after,
animals were exposed to two novel black plastic cylin-
ders (8 cm tallr3.5 cm in diameter), affixed to the floor
and symmetrically placed at 6 cm from the two nearest
walls. Mice were placed in a corner, facing the centre and
at equal distance from the two objects. Their start position
was rotated and counterbalanced for each treatment
throughout the test. Twenty-four hours later, mice were
placed in the same cage for long-term memory testing.
One of the cylinders was replaced by a novel plastic rec-
tangular block (6 cm tallr3r3 cm), which was placed in
a counterbalanced fashion to avoid experimental bias.
Behaviours for both sessions were videotaped for 15 min.
Analysis included the number and total duration of ex-
ploratory approaches between novel and familiar objects.
Exploration was defined as sniffing or touching either of
the two objects with the snout ; sitting on the object was
not considered exploration. In the second exploration
trial, an object exploration index was calculated as the
ratio of the duration of the exploratory approaches tar-
geting the novel objects over the time of exploration of
both objects. The locomotor activity was defined as the
number of crossings on a grid superimposed onto the
image of each cage in a video monitor.
Statistical analyses
Normality and homoscedasticity of data distribution
were verified using the Kolmogorov–Smirnov and
Bartlett’s test. Parametric analyses were performed with
one-way analyses of variance (for repeated measures or
independent factors, as appropriate), followed by
Tukey’s test with Spjøtvoll–Stoline correction for post-hoc
comparisons. Non-parametric comparisons were carried
out by Kruskal–Wallis test, followed by Nemenyi’s test
for post-hoc comparisons. Significance threshold was set
at p=0.05.
Results
Sensorimotor functions, tactile sensitivity and thermal
nociception
In an initial set of experiments, we ascertained that IVM
did not exert any significant effect on reflex and home-
cage activity (data not shown). We then studied the
ability of IVM to modify haptic perception and somato-
sensory coordination in the sticky tape test. The P2X4
positive allosteric modulator did not significantly affect
the latency to remove the tape from the forepaws of the
mice (F2,15=0.02, n.s. ; Fig. 1a). Furthermore, in consider-
ation of the role of P2X in pain modulation (Toulme et al.
2010b), we tested its effects on acute thermal nociception
in the hot-plate test. However, IVM did not modify the
latency to the first paw-licking episode in mice, at either
47.5 xC (F2,17=1.51, n.s. ; Fig. 1b) or 50 xC (F2,17=1.69, n.s. ;
Fig. 1c).
Novel open field
We evaluated the effects of IVM in the regulation of the
locomotor and exploratory responses within a novel open
field. While IVM did not induce significant variations of
locomotor activity (F2,15=2.12, n.s. ; Fig. 2a), it dose-
dependently reduced the time spent in the centre
(F2,15=8.29, p<0.01 ; Fig. 2b), as well as the percent
locomotor activity in the centre (F2,15=6.46, p<0.01 ;
Fig. 2c). In contrast, no differences were detected between
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treatment groups in meandering (F2,15=2.50, n.s. ; Fig. 2d),
number of rears (F2,15=1.80, n.s. ; Fig. 2e) or the percent-
age of time spent moving (F2,15=2.04, n.s. ; Fig. 2f).
Collectively, these data indicate that IVM enhanced the
thigmotactic responses evoked in mice by a novel open
arena in mice, without modifying their exploratory be-
haviour.
Elevated plus maze
To further qualify the role of IVM in the regulation of
anxiety-like responses, we tested a separate group of
mice in the elevated plus maze paradigm. The highest
IVM dose significantly increased the time spent in open
arms (F2,20=5.73, p<0.05 ; Fig. 3a). This effect was ac-
companied by a significant decrease in the closed arm
duration (F2,20=8.00, p<0.01 ; Fig. 3b) and an increase in
the time spent on the central platform (F2,20=10.17,
p<0.01 ; Fig. 3c). Administration of the highest dosage of
IVM also significantly elevated the number of total en-
tries (F2,20=10.84, p<0.001; Fig. 3d). Additionally, treat-
ment with the 10 mg/kg dose of IVM resulted in
increments of head dips (F2,20=5.54, p<0.05 ; Fig. 3e) and
rears (F2,20=6.10, p<0.01 ; Fig. 3f). Conversely, the
2.5 mg/kg dose of IVM did not elicit any significant effect
in any of the aforementioned parameters. No significant
differences were found in stretch-attend postures (data
not shown). Taken together, these data show that the
10 mg/kg dose of IVM increased the exploratory activity
and reduced anxiety-like reactions in the elevated plus
maze, without exerting significant effects on risk assess-
ment.
Marble burying
In line with the effects of IVM in the elevated plus
maze, the highest dose of this agent (10 mg/kg i.p.)
elicited a significant decrease in marble-burying activity
(F2,26=16.04, p<0.001 ; Fig. 4a). The 10 mg/kg dose also
induced a decrease in digging duration (F2,25=4.34,
p<0.05 ; Fig. 4b), but not number of digging bouts
(F2,25=2.35, n.s. ; Fig. 4c).
Tail suspension
We proceeded with the assessment of IVM’s effects
on depression-related responses in mice. In the tail-
suspension paradigm, the 2.5 mg/kg dose of the drug
significantly increased immobility time in comparison to
both the vehicle and the 10 mg/kg dose (F2,18=11.17 ;
Fig. 5a). No significant difference, however, was found
between animals treated with the 10 mg/kg dose and
vehicle. IVM did not induce significant changes in latency
to immobility (H2, 21=2.14, n.s. ; data not shown).
Forced swim test
In the forced swim paradigm, IVM treatment induced a
dose-dependent increase in the duration of immobility
(F2,24=3.54, p<0.05 ; Fig. 5b). Post-hoc analyses revealed
that this effect was due to the difference between the
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10 mg/kg dose and the vehicle (p<0.05). A statistical
trend was also detected between the 2.5 mg/kg dose and
the vehicle (p<0.10). No significant difference was found
between the groups treated with the two IVM doses.
Similar to the results in the tail-suspension tests,
IVM failed to affect the latency to immobility (F2,25=0.10,
n.s.).
Conditioned place preference
In the CPP test, IVM did not elicit any overt rewarding or
aversive effect, as indicated by the absence of significant
changes in preference for the drug-paired compartments
(F2,19=0.24, n.s. ; Fig. 5c). No significant differences were
found in either locomotor activity during the pre- and
post-conditioning phases or in the differences of time
spent in the other compartment of the apparatus (data
not shown).
PPI of the acoustic startle
Treatment with IVM did not induce significant alter-
ations of acoustic startle magnitude (F2,12=2.82, n.s. ;
Fig. 6a). The drug, however, elicited a significant PPI re-
duction (treatment : F2,12=9.65, p<0.01 ; Fig. 6b). Post-hoc
analysis revealed that mice treated with 10 mg/kg IVM
showed a significantly lower PPI than both the groups
treated with vehicle (p<0.01) and 2.5 mg/kg IVM
(p<0.05).
Novel object exploration/recognition
As shown in Fig. 7a, IVM decreased the duration of novel
object exploration (F2,18=3.49, p=0.05). This effect was
due to a significant difference between the IVM doses of
2.5 and 10 mg/kg (p<0.05). While the drug did not
have any effect on the number of exploratory approaches
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directed towards the objects (F2,18=0.58, n.s. ; Fig. 7b), it
did affect the mean duration of each sniffing episode
(F2,19=3.75, p<0.05 ; data not shown). Further scrutiny of
this latter effect depended on a significant difference be-
tween the two doses of IVM (p<0.05), as well as by a
statistical trend (p<0.10) between vehicle and 2.5 mg/kg
IVM (Tukey). No difference in preference between
the two objects was detected in any of the treatment
groups.
The P2X4 receptor activator failed to affect the
mnemonic encoding of novel objects, as revealed by the
equivalence of the novel exploration index at 24 h after
the first exposure (F2,18=0.82, n.s. ; Fig. 7c). In line with the
results from the open field, no significant differences
were observed in locomotor activity between treatment
groups (data not shown).
Behavioural effects of IVM in P2X4 KO mice
To verify whether the observed behavioural effects of
IVMwere mediated by P2X4 receptors, we tested the high
dose (10 mg/kg i.p.) of this compound in P2X4 KO mice
across the main paradigms significantly affected by it. In
the open field, IVM evoked a spectrum of responses
similar to those observed in WT mice, including the
lack of changes in overall distance (F1,12=0.04, n.s. ;
Fig. 8a), as well as significant reductions in time
(F1,13=22.61, p<0.001; Fig. 8b) and percent distance trav-
elled in the centre quadrant (F1,12=54.76, p<0.001;
Fig. 8c).
In the elevated plus maze, IVM significantly increased
the duration of time spent in the open arms (F1,13=6.04,
p<0.05 ; Fig. 8d) and reduced the time spent in the closed
arms by P2X4 KO mice (F1,13=14.49, p<0.01 ; Fig. 8e). In
addition, IVM-treated P2X4 KOmice exhibited significant
enhancements in the total number of arm entries
(F1,13=11.43, p<0.01 ; Fig. 8f)] and head dips (F1,13=11.75,
p<0.01 ; Fig. 8g).
In contrast with the effects of IVM in WT mice, this
drug significantly increased startle amplitude (F1,11=6.25,
p<0.05 ; Fig. 8e) but did not reduce %PPI (F3,9=1.30, n.s. ;
Fig. 8f).
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Discussion
The results of the present study document that acute
administration of IVM resulted in a complex set of effects
on the regulation of emotional, cognitive and perceptual
functions. In particular, the drug exhibited a multi-
faceted, complex profile with regard to complementary
aspects of anxiety-like responsiveness. IVM induced a
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highly heterogeneous array of behavioural responses
across different anxiety-related tasks. In a novel open
field, mice treated with this drug displayed a dose-
dependent increase in thigmotaxis, which was not
accompanied by any other significant variation in loco-
motor and exploratory parameters. While these results
are generally associated with anxiogenic-like effects (Prut
& Belzung, 2003), this interpretation is in stark contrast to
the finding that the 10 mg/kg (but not 2.5 mg/kg) dose
of IVM exerted a marked reduction of anxiety-like
behaviours in the elevated plus maze and marble-
burying assays.
The discrepancies among IVM-induced effects on
anxiety-like responses are likely to reflect the differential
impact of this drug on diverse aspects of anxiety-related
and exploratory responses. Although the ethological
construct underlying most paradigms for anxiety testing
in rodents is based on the conflict between exploration
and neophobia in response to different environmental
cues, several studies have documented that each test
captures different dimensions of anxiety-related respon-
siveness (Belzung & Le Pape, 1994 ; Carola et al. 2002;
Ramos et al. 1997).
Additionally, IVM increased depression-associated
indices in both the tail suspension and forced swim
tests and reduced sensorimotor gating in the PPI assay.
These results suggest that IVM induced depression-like
reactions (albeit at different doses) in response to acute,
inescapable stressors. Both assays carry high predictive
validity for depression and treatments that increase im-
mobility duration are generally interpreted to worsen
mood, particularly if, like IVM, they elicit no intrinsic
hypolocomotion or sedation. Although previous reports
indicated that very high doses of IVM induced signs
of depression in animals (Basudde, 1989), the increased
immobility in these studies is unlikely to reflect the same
phenomena, since they were elicited by the low IVM dose
in the tail suspension and not associated by any sign of
acute toxicity in this or other studies (Yardley et al. 2012).
Notably, we found divergent dose–response relations
of IVM-induced depressive-like effects in the tail-
suspension test (in which immobility was observed in
response to the 2.5 mg/kg, but not 10 mg/kg, dose) and
in the forced swim test (which resulted in immobility
only at the dose of 10 mg/kg). The differences between
these two results are currently unknown, but they may
reflect different sensitivities of these two paradigms to
the various neurotransmitter systems that regulate
stress reactivity. Indeed, although both paradigms are
based on the same ethological construct, based on
the immobility caused by inescapable situations
(Castagné et al. 2011), they have been shown to respond
differently to several pharmacological agents (Chatterjee
et al. 2012).
Another interesting finding of our studies was that,
in WT mice, IVM induced a dose-dependent reduction
in PPI, without affecting acoustic startle magnitude,
signifying that this drug has an acute impact on sensori-
motor gating and information processing. This finding is
in line with previous reports (Davis et al. 1999), which
documented PPI deficits following long-term adminis-
tration of IVM in drinking water to mice. These impair-
ments are connected to a broad set of neuropsychiatric
deficits, ranging from psychotic disorders to obsessive–
compulsive disorder and attention-deficit hyperactivity
disorder. In addition, pharmacological disruptors of PPI
in rodents have been shown to elicit psychotomimetic
effects in humans. Irrespective of these considerations, it
is interesting to note that IVM-induced gating impair-
ments did not overtly affect declarative mnemonic en-
coding, as revealed by the novel object recognition test.
This observation tempers the possibility that the ob-
served changes in PPI may have a repercussion on cog-
nition and learning.
It is relevant to note that IVM did not elicit overt re-
warding and/or aversive actions in the CPP test. As the
rewarding effects of a drug are regarded as a necessary
premise for abuse and dependence, these data strongly
suggest that IVM does not significantly modify incentive
behaviour. Given the biased design of our protocol
(which was used to enhance the sensitivity of the test to
the potential rewarding effects of IVM), the apparent lack
of aversive effects remains inconclusive, as it may
be masked by potential floor effects. Irrespective of this
issue, the lack of inherent addictive potential of IVM is in
line with the absence of clinical notes on its recreational
consumption in humans and is particularly important in
view of the recent finding that this drug reduces alcohol
intake in mice, as measured in several models (Yardley
et al. 2012).
To our knowledge, few studies have been published on
the behavioural effects of IVM in rodents. In line with our
findings, previous work showed the lack of effects of this
drug on general parameters of health and motor coordi-
nation in mice and rats (Davis et al. 1999; Nafstad et al.
1991). Davis et al. (1999) found that prolonged adminis-
tration of IVM in tap water elicited significant psycho-
tropic effects in several murine strains, including an
enhancement in motor and acoustic reactivity as well as
an attenuation of gating, but that it did not alter spatial
learning. Furthermore, i.p. injections of low IVM doses
were found to exert rapid anxiolytic-like properties in the
elevated plus maze and Vogel test in rats (de Spinosa et al.
2002). Although these findings cannot be directly com-
pared to our results, in view of differences in regimens of
administration and species (or strains) tested, our study
confirmed that IVM exerts psychotropic properties and
induces a complex array of effects on emotional regu-
lation.
The multi-faceted behavioural profile of IVM across
the tests in this study is likely to reflect the involvement
of multiple, divergent neurochemical targets of this drug,
also in relation to the different sensitivity of each para-
digm to different systems. In mammals, high-affinity
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binding sites for IVM have been characterized on GABAA
(Huang & Casida, 1997) and P2X4 receptors (Priel &
Silberberg, 2004).
Given the lack of available effective P2X4 receptor
antagonists, we tested the effects of P2X4 KO mice to
identify the specific contributions of this target to IVM-
induced behavioural effects. The effects of IVM remained
substantially unaltered in the open field and elevated
plus maze, suggesting that P2X4 receptors do not play a
critical role in the modulation of anxiety-related re-
sponses in paradigms based on the conflict between ap-
proach and avoidance with regard to unprotected
environments. Thus, it is likely that the apparently anti-
thetical effects of IVM in the open field and elevated plus
maze may reflect the impingement of other receptors. For
example, the behavioural changes in the elevated plus
maze are in line with the anxiolytic-like properties of
GABAA receptor agonists (Davis et al. 1999).
In contrast, IVM elicited significantly divergent effects
in WT and P2X4 KO mice with regard to startle and PPI.
In particular, IVM enhanced the startle amplitude of P2X4
KO mice, suggesting a role of these receptors in the
regulation of acoustic startle response. Further research
will be needed to fully understand the specific neuro-
biological underpinnings of the role of these targets in the
modulation of startle.
In addition, we found that IVM did not induce any
impairments of PPI in P2X4 KO mice, suggesting that the
deficits in sensorimotor gating caused by this drug were
in fact mediated by P2X4 receptor activation.
Although the tail-suspension effects of IVM were
not tested in P2X4 KO mice, the enhancement of tail-
suspension immobility by IVM is also unlikely to strictly
reflect the outcomes of GABAA activation, as this effect
is dose-dependent and reflects a reduction in overall
locomotor activity (Steru et al. 1987). Given that tail-
suspension and forced swim behaviours are poorly sen-
sitive to the outcomes of GABAA receptor activation
(Borsini & Meli, 1988 ; Steru et al. 1987), it is possible
that IVM-induced responses may reflect a more promi-
nent influence by P2X4 receptors. These results indicate
that positive allosteric modulation of P2X4 receptors may
directly modulate emotional reactivity in response
to acute stressors, possibly inducing anxiety- and de-
pression-like responses. Complementary to this idea,
previous studies suggest that the behavioural effects of
some antidepressant agents may in fact be mediated by
the blockade of P2X4 receptors, (Sim & North, 2010;
Toulme et al. 2010b ; for contrasting results see Nagata
et al. 2009).
Recent evidence suggests that P2X4 receptors may
negatively interact with the effects of GABAA receptor
activation (Jo et al. 2011), providing a possible expla-
nation for the contrasting outcomes observed across dif-
ferent tests. In particular, it is possible that P2X4 receptor
activation may induce aversive effects, which may
contrast the rewarding properties of GABAA receptor
activation. Thus, the simultaneous stimulation of both
targets may reduce the addictive potential associated
with GABAA receptor agonists.
The identification of novel pharmacological targets for
behavioural regulation is a task of paramount import-
ance, in consideration of the largely inadequate thera-
peutic armamentarium for neuropsychiatric conditions.
The translational implications of our data afford a
broader perspective on the behavioural effects of IVM.
Further studies are necessary to qualify the nature of the
potentially untoward effects documented by this study,
such as the increase in depression-like responses and the
sensorimotor gating deficits. Our results point to a role of
P2X4 receptors in the modulation of startle responsive-
ness, as well as sensorimotor gating. Future studies with
selective antagonists or small interfering RNAs for P2X4
receptors will be critical to ascertain the implication of the
activation of these targets. Irrespective of these aspects,
the lack of rewarding properties of IVM in the CPP
paradigm, its anxiolytic-like properties in two comp-
lementary paradigms for anxiety-related behaviours and
its ability to attenuate alcohol intake (Yardley et al. 2002)
strongly suggest that IVM and its derivatives may be of
great interest for the development of novel therapeutic
avenues in neuropsychiatric therapy.
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